Table 3. Comparison of the distribution of parameters, AUC, sensitivity, specificity, PPV and NPV in the development and validation cohorts of MRS-COVID-19 score.
| Development cohort n = 1270 | Validation cohort n = 800 | |
|---|---|---|
| Patients with missing data | 270 | 185 |
| AUC | 0.81 | 0.80 |
| Sensitivity -% (95% CI) | 95.83 (91.65–97.97) | 92.52 (85.94–96.16) |
| Specificity -% (95% CI) | 41.46 (38.16–44.85) | 41.34 (37.14–45.67) |
| PPV -% (95% CI) | 24.85 (21.67–28.31) | 24.94 (20.93–29.42) |
| NPV -% (95% CI) | 98.01 (95.95–99.03) | 96.33 (92.93–98.13) |
| Mortality (%) | 16.81 | 17.39 |
| Age categorized- n (%) | ||
| ≤50 | 244 (19.23) | 159 (19.88) |
| 51–60 | 245 (19.32) | 134 (16.75) |
| 61–70 | 238 (18.75) | 175 (21.87) |
| 71–80 | 273 (21.51) | 164 (20.50) |
| >80 | 269 (21.19) | 168 (21.00) |
| Gender- n (%) | ||
| Male | 729 (57.40) | 457 (57.12) |
| Female | 541 (42.60) | 343 (42.88) |
| Arterial hypertension- n (%) | ||
| No | 694 (54.86) | 446 (56.17) |
| Yes | 571 (45.14) | 348 (43.83) |
| Diabetes mellitus- n (%) | ||
| No | 999 (78.97) | 651 (81.98) |
| Yes | 266 (21.03) | 143 (18.02) |
| Pulmonary disease- n (%) | ||
| No | 1049 (83.05) | 667 (84.01) |
| Yes | 214 (16.95) | 127 (15.99) |
| Cardiovascular disease- n (%) | ||
| No | 1061 (84.07) | 671 (84.51) |
| Yes | 201 (15.93) | 123 (15.49) |
| Renal Failure- n (%) | ||
| No | 1011 (96.19) | 654 (95.47) |
| Yes | 40 (3.81) | 31 (3.53) |
| Thrombocytopenia- n (%) | ||
| No | 1048 (84.17) | 565 (79.58) |
| Yes | 197 (15.83) | 137 (20.42) |
| Prolonged PT- n (%) | ||
| No | 952 (80.81) | 565 (79.58) |
| Yes | 226 (19.19) | 145 (20.42) |
| D-dimer elevated (>2 ULN)- n (%) | ||
| No | 728 (70.47) | 457 (70.85) |
| Yes | 305 (29.53) | 188 (29.15) |
AUC = area under the curve; NPV = negative predictive value; PPV = positive predictive value; ULN = upper limit of normality.